6578 Stock Overview
DaBomb Protein Biotech Corp., a specialized biotech company, primarily engages in the development of antibiotics alternatives in animal health industry.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 1/6 |
DaBomb Protein Biotech Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$29.40 |
| 52 Week High | NT$31.50 |
| 52 Week Low | NT$15.70 |
| Beta | 0.60 |
| 1 Month Change | 24.31% |
| 3 Month Change | 37.70% |
| 1 Year Change | 57.22% |
| 3 Year Change | 44.38% |
| 5 Year Change | 19.78% |
| Change since IPO | -7.39% |
Recent News & Updates
Shareholder Returns
| 6578 | TW Personal Products | TW Market | |
|---|---|---|---|
| 7D | 4.4% | -6.0% | -5.7% |
| 1Y | 57.2% | -15.8% | 23.8% |
Return vs Industry: 6578 exceeded the TW Personal Products industry which returned -15.8% over the past year.
Return vs Market: 6578 exceeded the TW Market which returned 23.8% over the past year.
Price Volatility
| 6578 volatility | |
|---|---|
| 6578 Average Weekly Movement | 8.5% |
| Personal Products Industry Average Movement | 3.9% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6578's share price has been volatile over the past 3 months.
Volatility Over Time: 6578's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of TW stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | n/a | Yu Fen Liu | www.dabombprotein.com |
DaBomb Protein Biotech Corp., a specialized biotech company, primarily engages in the development of antibiotics alternatives in animal health industry. It offers plant protein, including DaBomb-P (Aqua) and DaBomb-P (Livestock); antibiotics alternatives, such as DBT-100 HT and DBT-100 LS; and pet care products comprising LACTOTIDES HEALTH A+ and Liqui-TIDE bandages. The company was formerly known as DaBomb Protein Corp. and changed its name to DaBomb Protein Biotech Corp. in October 2023.
DaBomb Protein Biotech Corp. Fundamentals Summary
| 6578 fundamental statistics | |
|---|---|
| Market cap | NT$1.76b |
| Earnings (TTM) | -NT$57.02m |
| Revenue (TTM) | NT$384.41m |
4.6x
P/S Ratio-30.8x
P/E RatioIs 6578 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6578 income statement (TTM) | |
|---|---|
| Revenue | NT$384.41m |
| Cost of Revenue | NT$337.99m |
| Gross Profit | NT$46.43m |
| Other Expenses | NT$103.45m |
| Earnings | -NT$57.02m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.96 |
| Gross Margin | 12.08% |
| Net Profit Margin | -14.83% |
| Debt/Equity Ratio | 43.4% |
How did 6578 perform over the long term?
See historical performance and comparison